Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy

AIDS

Volumn 14, Issue 1, 2000, Pages 31-36

  Precious, Heather M ^a   Günthard, Huldrych F ^b   Wong, Joseph K ^b   D'Aquila, Richard T ^c   Johnson, Victoria A ^d   Kuritzkes, Daniel R ^e   Richman, Douglas D ^b   Leigh Brown, Andrew J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; HIV drug resistance; HIV sequence variability; Reverse transcriptase inhibitors; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; NONHUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS; VIRUS LOAD; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NEVIRAPINE; PLACEBOS; POINT MUTATION; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, PROTEIN; VIRAL LOAD; ZIDOVUDINE;

EID: 0033959515     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001070-00004     Document Type: Article

References (32)

1. 1. Richman D, Shih CK, Lowys I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991, 88:11241-11245.
2. 2. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
3. 3. Tisdale M, Kemp, SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-3656.
4. 4. Schuurman R, Nijhuis M, Van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
5. 5. Kellam P, Boucher CAB, Tijnagel JMCH, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994, 75:341 -351.
6. 6. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
7. 7. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
8. 8. Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug resistant HIV-1 in vitro. Nature 1993, 365:451-453.
9. 9. Shiraska T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
10. 10. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (norvir) monotherapy. J Virol 1998, 72:5154-5164.
11. 11. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, 174:704-712.
12. 12. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4-lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
13. 13. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995 9:159-163.
14. 14. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:929-938.
15. 15. Lorenzi P, Opravil, M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999, 13: F17-F21.
16. 16. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
17. 17. St. Clair MH, Hartigan PH, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993, 6:891 -897.
18. 18. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
19. 19. Larder BA, Kemp SD, Harrigan R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
20. 20. Rose RE, Gong YF, Creytok JA, et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996, 93:1648-1653.
21. 21. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998, 12:1015-1020.
22. 22. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998, 72:5093-5098.
23. 23. Leigh Brown AJ. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci USA 1997, 94:1862-1865.
24. 24. Leigh Brown AJ, Richman DD. HIV-1: Gambling on the evolution of drug resistance? Nature Med 1997, 3:268-271.
25. 25. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and dianosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996, 124:1019-1030.
26. 26. Gunthard HF, Leigh Brown AJ, D'Aquila RT, et al. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. Virology 1999, 259:154-165.
27. 27. Human Retroviruses and AIDS 1997: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. (Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory).
28. 28. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1996, 4: 95-107.
29. 29. Leigh Brown AJ, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptases are associated with subsequent virological response to antiretroviral therapy. J Infect Dis 1999, 180: 1043-1049.
30. 30. Bloor S, Hertog K, De Vroey V, Miller V, Sturmer M, Larder B. Lamivudine - resistant HIV-1 clinical isolates lacking the Met184Val mutation have novel polymorphisms in RT. Third International Workshop on Drug Resistance and Treatment Strategies. San Diego. June 1999 [abstract 25].
31. 31. Najera I, Holguin A, Quinones-Mateu ME, et al. pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
32. 32. Rubsamen-Waigmann H, Schroder B, Biesert L, et al Markers for HIV-disease progression in untreated patients and patients receiving AZT: Evaluation of viral activity, AZT resistance, serum cholesterol, b2-microglobulin, CD4+ cell counts, and HIV antigen. Infection 1991, 19 (suppl 2): S77-S82.